

Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects

Marco Solmi¹⁻³, Michele Fornaro⁴, Edoardo G. Ostinelli^{5,6}, Caroline Zangani⁶, Giovanni Croatto¹, Francesco Monaco⁷, Damir Krinitski⁸, Paolo Fusar-Poli^{3,9-11}, Christoph U. Correll¹²⁻¹⁵

¹Neurosciences Department, University of Padua, Padua, Italy; ²Padua Neuroscience Center, University of Padua, Padua, Italy; ³Early Psychosis: Interventions and Clinical-detection (EPIC) lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK; ⁴Department of Psychiatry, Federico II University, Naples, Italy; ⁵Oxford Health NHS Foundation Trust, Warneford Hospital, and Department of Psychiatry, University of Oxford, Oxford, UK; ⁶Department of Health Sciences, University of Milan, Milan, Italy; ⁷Department of Mental Health, ASL Salerno, Salerno, Italy; ⁸Integrated Psychiatry Winterthur (IPW), Winterthur, Switzerland; ⁹OASIS Service, South London & Maudsley NHS Foundation Trust, London, UK; ¹⁰Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy; ¹¹National Institute for Health Research, Maudsley Biomedical Research Centre, South London & Maudsley NHS Foundation Trust, London, UK; ¹²Department of Psychiatry, Zucker Hillside Hospital, Northwell Health, Glen Oaks, New York, NY, USA; ¹³Department of Psychiatry and Molecular Medicine, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA; ¹⁴Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, NY, USA; ¹⁵Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin Berlin, Berlin, Germany

Mental disorders frequently begin in childhood or adolescence. Psychotropic medications have various indications for the treatment of mental disorders in this age group and are used not infrequently off-label. However, the adverse effects of these medications require special attention during developmentally sensitive periods of life. For this meta-review, we systematically searched network meta-analyses and meta-analyses of randomized controlled trials (RCTs), individual RCTs, and cohort studies reporting on 78 a priori selected adverse events across 19 categories of 80 psychotropic medications – including antidepressants, antipsychotics, anti-attention-deficit/hyperactivity disorder (ADHD) medications and mood stabilizers – in children and adolescents with mental disorders. We included data from nine network meta-analyses, 39 meta-analyses, 90 individual RCTs, and eight cohort studies, including 337,686 children and adolescents. Data on ≥20% of the 78 adverse events were available for six antidepressants (sertraline, escitalopram, paroxetine, fluoxetine, venlafaxine and vilazodone), eight antipsychotics (risperidone, quetiapine, aripiprazole, lurasidone, paliperidone, ziprasidone, olanzapine and asenapine), three anti-ADHD medications (methylphenidate, atomoxetine and guanfacine), and two mood stabilizers (valproate and lithium). Among these medications with data on ≥20% of the 78 adverse events, a safer profile emerged for escitalopram and fluoxetine among antidepressants, lurasidone for antipsychotics, methylphenidate among anti-ADHD medications, and lithium among mood stabilizers. The available literature raised most concerns about the safety of venlafaxine, olanzapine, atomoxetine, guanfacine and valproate. Nausea/vomiting and discontinuation due to adverse event were most frequently associated with antidepressants; sedation, extrapyramidal side effects, and weight gain with antipsychotics; anorexia and insomnia with anti-ADHD medications; sedation and weight gain with mood stabilizers. The results of this comprehensive and updated quantitative systematic meta-review of top-tier evidence regarding the safety of antidepressants, antipsychotics, anti-ADHD medications and mood stabilizers in children and adolescents can inform clinical practice, research and treatment guidelines.

Key words: Safety, tolerability, children, adolescents, psychopharmacology, antidepressants, antipsychotics, mood stabilizers, psychostimulants, meta-review

(*World Psychiatry* 2020;19:214–232)

Childhood and adolescence are a crucial time of biopsychosocial development¹. Many, if not most, severe mental disorders have their onset prior to age 18². Early intervention is a cornerstone of modern psychiatry which has demonstrated superior outcomes, for example, in psychotic disorders and bipolar disorder^{3,4}. In addition to psychotherapeutic and psychosocial interventions, psychotropic medications are often necessary to treat severe mental disorders that result in subjective distress and/or significant dysfunction in youth.

Several antidepressants, antipsychotics, anti-attention-deficit/hyperactivity disorder (ADHD) medications and mood stabilizers indicated in adults have received regulatory approval for use in children and/or adolescents⁵, and many are used off-label⁶⁻¹⁰. However, despite evidence for the efficacy of a number of psychotropic medications in youth, the duration of untreated illness in depressive disorder¹¹, bipolar disorder^{12,13}, schizophrenia¹⁴, obsessive-compulsive disorder¹⁵, anxiety disorders¹⁶, and other mental disorders¹⁷ is often long^{18,19}, which adversely af-

fects long-term outcomes^{14,20-24}. Such delay can be related to several factors. These certainly include reduced access to care due to stigma and self-stigma surrounding mental illness²⁵⁻²⁷, but stigma-derived or data-based concerns about the safety of psychotropic medications in children and adolescents are also relevant²⁸⁻³⁴.

The poor quality of data on safety of psychotropic medications can potentially induce a delay or refusal of treatment, despite evidence that medications used in psychiatry are generally not less effective than those prescribed in other fields of medicine³⁵. For instance, poor reporting of adverse events in available randomized controlled trials (RCTs) may have led to inaccurate estimates of some serious events, such as suicidality with antidepressants³⁶. In addition, regulatory agencies may issue boxed warnings for adverse events of medications, such as for antidepressants increasing suicidality in children, adolescents and young adults³⁷, which can impact prescribing habits in everyday clinical practice³⁸, but whose validity may then be ques-

tioned^{39,40}. At the same time, evidence-based safety concerns and warnings are essential to inform treatment guidelines and clinical care and are crucial to protect patients according to the *primum non nocere* principle.

The evidence on safety of psychotropic agents in children and adolescents with mental disorders has been rapidly growing⁴¹, but remains fragmented. The available network meta-analyses (NMAs) and meta-analyses (MAs) have generally considered efficacy as their primary outcome, while safety is usually not prioritized in the primary RCTs and related evidence syntheses. Moreover, NMAs and MAs only include RCTs, usually concerning one or, rarely, few related mental disorders.

While RCTs minimize the influence of several sources of bias on estimates of medication effects in a specific population, they also apply strict selection criteria, which reduces the generalizability and external validity of their findings. Moreover, RCTs are often relatively small and short in duration, which precludes the adequate identification of rare but serious or long-term adverse events⁴². Furthermore, NMAs and MAs generally focus on the use of medications in disorders for which they are indicated, excluding evidence about off-label use. Therefore, a comprehensive summary of the evidence concerning the safety of psychotropic medications for all the mental health conditions for which they are used in children and adolescents, based on RCTs as well as on large cohort studies including more generalizable samples and reflecting real-world use patterns, is important to inform clinical practice.

To the best of our knowledge, no systematic meta-review exists to date that has focused on the safety of psychotropic drugs in children and adolescents as its primary outcome, summarizing data from NMAs, MAs, largest individual RCTs, and well-designed matched cohort studies across all relevant mental disorders. The aim of the present meta-review was to provide the largest and most comprehensive evidence synthesis on the safety of four major psychotropic medication classes (antidepressants, antipsychotics, anti-ADHD drugs, mood stabilizers) in children and adolescents with mental disorders, in order to inform clinical decision making and guideline development, and to identify areas needing further research.

METHODS

Search, inclusion and exclusion criteria

This systematic meta-review followed an *a priori* protocol (available upon request). We conducted a systematic search in PubMed and PsycINFO, from database inception up to September 7, 2019, using an exhaustive combination of key words for both psychotropic medications and adverse health outcomes (full search string available upon request). Additional manual searches were performed on reference lists of included articles. Pairs of authors conducted title/abstract screening and full-text assessment, and extracted data into a pre-defined excel spreadsheet. A third author resolved any conflict.

Inclusion criteria were: a) NMAs, MAs, individual RCTs, and cohort studies controlling for confounding by indication (i.e., medication vs. placebo/no medication in subjects affected by the same disorder); b) data on the association between antidepressants, antipsychotics, anti-ADHD medications, or mood stabilizers and adverse health outcomes; c) population of children and/or adolescents with any mental disorder.

Exclusion criteria were: a) studies on conditions other than mental disorders for which psychotropic medications are indicated or used (e.g., epilepsy); b) confounding by indication (i.e., comparing patients on medications with healthy controls), even if they adjusted analyses for covariates; c) designs other than those indicated in inclusion criteria; d) no data on the association between the targeted medications and adverse health outcomes.

Included adverse events and psychotropic medications

The 78 *a priori* selected adverse events were subdivided into the following 19 categories: central nervous system (agitation, anxiety, asthenia, irritability, cognitive impairment, depression, dizziness, headache, mania, psychosis, sedation, insomnia, seizures, suicidal ideas/behaviors/attempts); nutritional and metabolic (anorexia, binge eating/increased appetite, increased cholesterol, increased triglycerides, metabolic syndrome, glucose dysregulation/diabetes, insulin resistance, increased waist circumference, weight gain/increased body mass index, weight loss); cardiovascular (arrhythmias/tachycardia, cardiomyopathy, cerebrovascular disease, coronary heart disease, hypertension, hypotension, myocarditis, QT prolongation, sudden cardiac death); gastrointestinal (abdominal pain, constipation, diarrhea, gastrointestinal symptoms, liver damage, nausea/vomiting); genitourinary (enuresis, kidney disease/failure, menstrual cycle alterations, polycystic ovarian syndrome, sexual dysfunction); movement disorders (akathisia, any extrapyramidal side effect, tremor, dystonia, tardive dyskinesia); impulse dyscontrol and risky behavior (criminal behavior, gambling, substance abuse, non-suicidal self-injury behaviors); endocrine (gynecomastia/galactorrhea, hypo/hyperprolactinemia, hypo/hyperthyroidism); hematologic (anemia, leukocytopenia, thrombocytopenia); mouth (dental caries, dry mouth, sialorrhea); respiratory (acute respiratory failure, asthma, nasopharyngitis/upper respiratory tract infection/pneumonia); venous thromboembolism (deep vein thrombosis, pulmonary embolism); bone health (osteopenia/osteoporosis, fractures); accidents (any accident, fall); neuroleptic malignant syndrome (neuroleptic malignant syndrome/fever/creatinine phosphokinase elevation); any cancer; discontinuation due to adverse event; serious adverse events; and mortality (all-cause, due to natural causes, due to suicide).

The 80 psychotropic medications were subdivided into the four categories of antidepressants, antipsychotics, anti-ADHD medications, and mood stabilizers. The category of antidepressants included nine classes: monoamine oxidase inhibitors (I-MAOs) (bifemelane, hydracarbazine, isocarboxazid, moclobemide,

nialamide, phenelzine, pirlindole, rasagiline, safinamide, selegiline, toloxatane and tranylcypromine); tricyclics (TCAs) and tetracyclics (TeCAs) (amitriptyline, amoxapine, clomipramine, desipramine, doxepine, imipramine, maprotiline, nortriptyline, protriptyline and trimipramine); selective serotonin reuptake inhibitors (SSRIs) (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine and sertraline); serotonin-noradrenaline reuptake inhibitors (SNRIs) (desvenlafaxine, duloxetine, levomilnacipran, milnacipran and venlafaxine); serotonin partial agonist and reuptake inhibitors (SPARIs) (nefazodone, trazodone and milazodone); noradrenergic and specific serotonergic antidepressants (NASSAs) (mianserin and mirtazapine); noradrenaline reuptake inhibitors (NRIs) (reboxetine); noradrenaline and dopamine reuptake inhibitors (NDRIs) (bupropion); others (agomelatine, esketamine, S-adenosyl-methionine and vortioxetine). The category of antipsychotics included two classes: first-generation antipsychotics (FGAs) (chlorpromazine, fluphenazine, haloperidol, loxapine, molindone, perphenazine, promazine and trifluoperazine) and second-generation antipsychotics (SGAs) (amisulpride, aripiprazole, asenapine, brexpiprazole, cariprazine, clozapine, iloperidone, lurasidone, olanzapine, paliperidone, quetiapine, risperidone and ziprasidone). Anti-ADHD medications included psychostimulants (d-amphetamine, lisdexamphetamine and methylphenidate) and medications with other mechanisms (atomoxetine, clonidine, guanfacine and modafinil). Mood stabilizers included antiepileptics (carbamazepine, gabapentin, lamotrigine, pregabalin, oxcarbazepine, topiramate and valproate) and lithium.

Primary and secondary outcomes

The primary outcome was the safety/coverage ratio (i.e., the number of adverse events significantly worse than placebo/no treatment over the number of adverse events covered by literature) for those psychotropic medications for which $\geq 20\%$ of the 78 *a priori* selected events were covered by the literature. The secondary outcomes were the list of adverse events associated with each medication, their effect size $\pm 95\%$ CI, and the study quality.

The magnitude of associations of each medication with the main adverse events was classified as small (≤ 0.5), medium (between >0.5 and <0.8) and large (≥ 0.8) for continuous outcomes (effect sizes >0) and inverse thresholds for effect sizes <0 . For categorical outcomes, the magnitude of associations was classified as small (<3), medium (between ≥ 3 and <5) and large (≥ 5) for equivalent odds ratios (eORs) >1 , and reciprocal thresholds for eORs <1 ⁴³.

Quality of evidence

The quality of MAs and NMAs was measured with a modified version of the A Measurement Tool for the Assessment of Multiple Systematic Reviews (AMSTAR)-PLUS⁴⁴, which allows to measure both the quality of the methodology of (N)MAs, and the quality of the studies included in (N)MAs (AMSTAR-Content).

AMSTAR quality was considered low when the final score was <4 , medium when it was 4-7, and high when >7 ⁴⁵. For AMSTAR-Content, quality was considered low when the final score was <4 , medium when it was 4-6, and high when >6 . The overall quality of (N)MAs was rated choosing the lower score of either AMSTAR or AMSTAR-Content.

The quality of RCTs was assessed with the Risk of Bias tool 2⁴⁶, assigning high risk, low risk, or some concerns. The quality of cohort studies was measured with the Newcastle-Ottawa Scale (NOS)⁴⁷, and high quality was assigned when the NOS score was ≥ 7 .

Statistical analysis

We extracted random effects effect sizes $\pm 95\%$ CIs for the difference in the incidence of specific adverse events between individual medications and placebo (RCTs), or between treated vs. untreated youth with mental disorders (cohort studies). We considered ORs, log ORs or risk ratios (RRs) with respective numbers-needed-to-harm (NNH) for categorical outcomes, and standardized mean differences (SMDs) or mean differences (MDs) for continuous outcomes.

We calculated the overall proportional coverage of the *a priori* selected adverse events for each of the individual psychotropic medications using descriptive statistics, and divided the covered adverse events into those with and without significantly higher frequencies vs. placebo or matched subjects. Furthermore, we identified medications with the best or worst safety/coverage ratio among those that had results for $\geq 20\%$ of the adverse events.

RESULTS

Search results

The flow chart of the search process for the three systematic searches is presented in Figure 1. At title and abstract level, we screened 1,309 hits for NMAs and MAs, 5,716 hits for individual RCTs and 8,518 hits for cohort studies. We assessed full texts of 292 articles for NMAs and MAs, 519 for individual RCTs, and 173 for cohort studies. We ultimately extracted data from nine NMAs, 39 MAs, 90 individual RCTs, and eight cohort studies, including 337,686 children and adolescents (120,637 for antidepressants, 66,764 for antipsychotics, 148,664 for anti-ADHD medications, and 1,621 for mood stabilizers).

For antidepressants, we included four NMAs^{40,48-50}, 15 MAs^{36, 51-64}, 27 individual RCTs⁶⁵⁻⁹¹ also covered in those NMA/MAs, six additional RCTs⁹²⁻⁹⁷, and three cohort studies⁹⁸⁻¹⁰⁰. There were 120,637 youth on antidepressants, including 24,659 across 139 RCTs after eliminating duplicated RCTs in multiple NMA/MAs (22,704 in NMA/MAs, 1,955 in additional RCTs), and 95,978 in three cohort studies.

For antipsychotics, we included three NMAs¹⁰¹⁻¹⁰³, 11 MAs¹⁰⁴⁻¹¹⁴,




Figure 1 PRISMA flow chart for inclusion of studies. Search 1: network meta-analyses (NMA) and meta-analyses (MA); Search 2: individual randomized controlled trials (RCTs); Search 3: cohort studies controlling for confounding by indication

25 individual RCTs¹¹⁵⁻¹³⁹ also included in those NMA/MAs, three additional RCTs¹⁴⁰⁻¹⁴², and two cohort studies^{99,143}. There were 66,764 youth on antipsychotics, including 7,712 across 53 RCTs after eliminating duplicated RCTs in multiple NMA/MAs (6,725 in NMA/MAs, 987 in additional RCTs), and 59,052 in two cohort studies.

For anti-ADHD medications, we included three NMAs^{49,144,145}, 11 MAs¹⁴⁶⁻¹⁵⁶, 12 RCTs¹⁵⁷⁻¹⁶⁸ also included in those NMA/MAs, five additional RCTs¹⁶⁹⁻¹⁷³, and five cohort studies^{99,174-177}. There were 148,664 youth on anti-ADHD medications, including 28,834 across 298 RCTs after eliminating duplicated RCTs in multiple NMA/MAs (27,188 in NMA/MAs, 1,646 in additional RCTs), and 119,830 in five cohort studies.

For mood stabilizers, we included four MAs^{107,112,178,179}, seven RCTs¹⁸⁰⁻¹⁸⁶ also included in those NMA/MAs, and five additional RCTs¹⁸⁷⁻¹⁹¹. There were 1,621 youth across 23 RCTs after eliminating duplicated RCTs in multiple NMA/MAs (1,244 in NMA/MAs, 377 in additional RCTs).

Quality of included evidence

Among nine NMAs, the median AMSTAR score was 10 (interquartile range, IQR=9-11) and the median AMSTAR-Content score was 5 (IQR=5-7). The quality was moderate in two (22.2%) NMAs, and high in the remaining seven NMAs (77.8%). The RCTs included in NMAs had moderate quality in six (66.7%) NMAs, and high qual-

ity in three (33.3%). The overall quality of the evidence from included NMAs was moderate in six (66.7%) and high in three (33.3%).

Among 39 MAs, the median AMSTAR score was 9 (IQR=7-10) and the median AMSTAR-Content was 5 (IQR=4-6). The quality was moderate in 11 MAs (28.2%), and high in the remaining 28 (71.8%). The RCTs included in MAs had low quality in nine (23.1%) MAs, moderate quality in 23 (59.0%), and high in seven (17.9%). The overall quality of the evidence from included MAs was low in nine (23.1%), moderate in 25 (64.1%) and high in five (12.8%).

Among 90 individual RCTs, 26 (28.6%) had high risk of bias, 43 (47.3%) raised some concerns, and 22 (24.2%) had low risk of bias.

Among eight cohort studies, six (75%) had a high quality according to the Newcastle-Ottawa scale, and the median quality score was 7 (IQR=7-8).

Overall safety of classes of psychotropic medications in children and adolescents with mental disorders

Antidepressants

Out of 44 antidepressants, 18 (40.9%) had adverse event data covered in the literature. The available antidepressant literature covered 0-24.4% (mean: 5.6%, median: 0%) of the reviewed adverse events. Details on the proportion of the 78 adverse events covered in the literature and of the adverse events that were sig-

nificantly worse with individual antidepressants vs. placebo/controls are reported in Table 1 and Figure 2.

Among antidepressants with $\geq 20\%$ of adverse events covered, the safety/coverage ratio was the best for escitalopram (1/17 adverse events covered significantly worse) and fluoxetine (1/16), progressively decreasing through vilazodone (2/16), paroxetine (3/16), sertraline (4/19), to venlafaxine, which had the worst safety/coverage ratio (7/16).

Five antidepressants were associated with significantly worse nausea/vomiting (duloxetine, nefazodone, paroxetine, sertraline, vilazodone), four with discontinuation due to adverse event (duloxetine, imipramine, venlafaxine, vilazodone), three with any extrapyramidal side effect (clomipramine, imipramine, paroxetine), two each with sedation (imipramine, nefazodone), diarrhea (duloxetine, sertraline), headache (nefazodone, venlafaxine), anorexia (amitriptyline, venlafaxine), and weight gain/increased body mass index (escitalopram, sertraline), and one each with weight loss (fluoxetine), and suicidality (venlafaxine).

Antipsychotics

Out of 21 antipsychotics, 15 (71.4%) had adverse event data covered in literature. The antipsychotic literature covered a range of 0-56.4% (mean: 16.6%, median: 2.6%) of the reviewed adverse events. Details of the proportion of the 78 adverse events covered in the literature and of adverse events that were significantly worse with individual antipsychotics vs. placebo/controls are reported in Table 2 and Figure 2.

Among antipsychotics with $\geq 20\%$ of adverse events covered, lurasidone had the best safety/coverage ratio (1/33 covered adverse events significantly worse), progressively decreasing through asenapine (2/22), quetiapine (5/37), ziprasidone (4/25), paliperidone (5/26), risperidone (12/44), aripiprazole (10/35), to olanzapine, which had the worst safety/coverage ratio (13/25).

Ten antipsychotics were associated with significantly worse sedation (aripiprazole, clozapine, haloperidol, loxapine, molindone, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone), nine with any extrapyramidal side effect (amisulpride, aripiprazole, haloperidol, loxapine, molindone, olanzapine, paliperidone, risperidone, ziprasidone), seven with weight gain/increased body mass index (aripiprazole, asenapine, clozapine, olanzapine, paliperidone, quetiapine, risperidone), five with hyperprolactinemia (haloperidol, olanzapine, paliperidone, quetiapine, risperidone), and three each with increased cholesterol (aripiprazole, olanzapine, quetiapine) and glucose increase/diabetes (asenapine, olanzapine, risperidone).

Anti-ADHD medications

All seven anti-ADHD medications had adverse event data covered in the literature. The available literature covered 7.7-32.1% (mean: 19.0%, median: 17.9%) of the reviewed adverse events. Details of the proportion of the 78 adverse events cov-

ered in the literature and of adverse events that were significantly worse with individual anti-ADHD medications vs. placebo/controls are reported in Table 3 and Figure 2.

Among anti-ADHD medications with $\geq 20\%$ of adverse events covered, methylphenidate had the best safety/coverage ratio (5/25 adverse events covered significantly worse), while guanfacine and atomoxetine had the worst safety/coverage ratio (4/16 and 5/20, respectively).

Five anti-ADHD medications were associated with significantly worse anorexia (atomoxetine, d-amphetamine, lisdexamphetamine, methylphenidate, modafinil), four with insomnia (d-amphetamine, lisdexamphetamine, methylphenidate, modafinil), three with weight loss (atomoxetine, methylphenidate, modafinil), two each with abdominal pain (methylphenidate, guanfacine), discontinuation due to adverse event (lisdexamphetamine, guanfacine), hypertension (atomoxetine, lisdexamphetamine), and sedation (clonidine, guanfacine), and one with QT prolongation (guanfacine).

Mood stabilizers

Out of eight mood stabilizers, six (75.0%) had adverse event data covered in the literature. The mood stabilizer literature covered 0-24.4% (mean: 12.7%, median: 14.1%) of the reviewed adverse events. Details on the proportion of the 78 adverse events covered in the literature and of adverse events that were worse with individual mood stabilizers vs. placebo/controls are reported in Table 4 and Figure 2.

Among mood stabilizers with $\geq 20\%$ of adverse events covered, the best safety/coverage ratio emerged for lithium (0/16 adverse events covered significantly worse), while valproate showed the worst safety/coverage ratio (4/19).

Two mood stabilizers were associated with significantly worse sedation (oxcarbazepine, valproate), and weight gain/increased body mass index (oxcarbazepine, valproate), and one each with weight loss or anorexia (topiramate), thrombocytopenia and leucocytopenia (valproate), and nausea/vomiting (oxcarbazepine).

Evidence from studies lasting ≥ 6 months

For antidepressants, no RCT lasted ≥ 6 months, while one cohort studies lasted 6 to 12 months¹⁰⁰, and two ≥ 12 months (range: 12-130 months)^{98,99}. Significant associations emerged between current mixed antidepressants and fractures (small effect size, ≥ 12 months), but this association became non-significant when considering past exposure to antidepressants. Also, while antidepressants had a small association (≥ 12 months) with increased risk of any cancer in the first version of the analyses from a large cohort study, additional analyses from the same database did not confirm such association when removing mixed medications⁹⁹.

For antipsychotics, no RCT lasted ≥ 6 months, no cohort study lasted 6-12 months, while two cohort studies lasted ≥ 12 months (range: 84-130 months)^{99,143}. A large association was found be-

Table 1 Safety of antidepressants in children and adolescents with any mental illness (adverse events significantly worse than with placebo/controls)

Medication	Adverse events		Adverse event	Type of effect size	Effect size	95% CI	Source	Quality	N
	covered by literature	worse than placebo							
Mixed antidepressants	12 (15.4%)	6 (7.7%)	Anorexia ⁴⁸	OR	4.01	1.63-10.17	NMA	M	26,114
			Discontinuation due to adverse event ⁵⁹	RR	1.66	1.20-2.28	MA	M	6,778
			Fractures ⁹⁸	HR	1.03	1.00-1.06	C	H	50,673
			Insomnia ⁶³	RR	2.16	1.42-3.27	MA	M	1,500
			Nausea/vomiting ⁶³	RR	1.88	1.44-2.45	MA	M	2,101
Mixed serotonin-noradrenaline reuptake inhibitors	9 (11.5%)	3 (3.8%)	Suicidality ⁵⁶	RR	1.95	1.28-2.98	MA	M	3,930
			Headache ⁶³	RR	1.52	1.09-2.13	MA	M	688
			Nausea/vomiting ⁶³	RR	1.97	1.36-2.87	MA	M	688
			Serious adverse events ⁵⁹	RR	2.10	1.19-3.69	MA	M	NA
Mixed selective serotonin reuptake inhibitors	14 (17.9%)	4 (5.1%)	Discontinuation due to adverse event ⁴⁹	Log OR	-1.8	-3.4 to -0.4	NMA	H	2,623
			Headache ⁶³	RR	1.27	1.03-1.56	MA	M	2,297
Mixed tricyclics	12 (15.4%)	4 (5.1%)	Nausea/vomiting ⁶³	OR	1.89	1.42-2.52	MA	M	831
			Serious adverse events ⁵⁹	RR	1.72	1.12-2.63	MA	M	NA
			Dry mouth ⁶³	RR	3.28	1.82-5.90	MA	M	232
			Hypotension ⁶⁴	OR	6.78	2.06-22.26	MA	L	324
			Tremor ⁶⁴	OR	6.29	1.78-22.17	MA	L	308
			Suicidality ⁴⁹	Log OR	25.1	4.5-57.4	NMA	H	2,623
			Anorexia ⁶⁵	NA	Sig	Sig	RCT	M	31
Amitriptyline	2 (2.6%)	1 (1.3%)							
Bupropion	8 (10.3%)	0 (0.0%)							
Citalopram	8 (10.3%)	0 (0.0%)							
Clomipramine	8 (10.3%)	1 (1.3%)	Any extrapyramidal side effects ⁹⁷	RR	9.35	1.28-68.6	RCT	M	60
Desipramine	6 (7.7%)	0 (0.0%)							
Desvenlafaxine	9 (11.5%)	0 (0.0%)							
Duloxetine	13 (16.7%)	3 (3.8%)	Diarrhea ⁹³	OR	3.26	1.09-9.71	RCT	H	556
			Discontinuation due to adverse event ⁴⁰	OR	2.80	1.20-9.42	NMA	H	5,260
Escitalopram	17 (21.8%)	1 (1.3%)	Nausea/vomiting ⁹³	OR	1.93	1.15-3.25	RCT	H	556
Fluoxetine	16 (20.5%)	1 (1.3%)	Weight gain ⁸⁷	OR	2.30	1.01-5.25	RCT	L	312
			Weight loss ⁷⁹	MD	-1.2	-1.85 to -0.55	RCT	M	103

Table 1 Safety of antidepressants in children and adolescents with any mental illness (adverse events significantly worse than with placebo/controls) (continued)

Medication	Adverse events covered by literature	Adverse events worse than placebo	Adverse event	Type of effect size	Effect size	95% CI	Source	Quality	N
Fluvoxamine	11 (14.1%)	1 (1.3%)	Abdominal pain ⁸⁹	RR	1.70	1.06-2.71	RCT	M	128
Imipramine	15 (19.2%)	5 (6.4%)	Any extrapyramidal side effects ⁹⁰ Discontinuation due to adverse event ⁴⁰	OR	7.35	1.62-33.3	RCT	M	182
			Dry mouth ⁶²	RR	3.81	1.25-11.6	MA	M	56
			Hypotension ⁹⁰	OR	13.6	1.74-107	RCT	M	182
			Sedation ⁹⁰	OR	4.44	1.22-16.2	RCT	M	182
Mirtazapine	2 (2.6%)	0 (0.0%)							
Nefazodone	8 (10.3%)	3 (3.8%)	Headache ⁹¹	NA	Sig	Sig	RCT	L	528
			Nausea/vomiting ⁹¹	NA	Sig	Sig	RCT	L	528
			Sedation ⁹¹	NA	Sig	Sig	RCT	L	528
Nortriptyline	3 (3.8%)	1 (1.3%)	Hypertension ⁶⁷	NA	Sig	Sig	RCT	M	50
Paroxetine	16 (20.5%)	3 (3.8%)	Any extrapyramidal side effects ⁹⁰	OR	5.12	1.09-24.1	RCT	M	180
			Insomnia ⁸²	OR	2.68	1.20-6.00	RCT	M	319
			Nausea/vomiting ⁶⁹	OR	3.69	1.01-13.5	RCT	L	319
Sertraline	19 (24.4%)	4 (5.1%)	Diarrhea ⁶⁸	OR	3.04	1.25-7.38	RCT	H	376
			Insomnia ⁸⁴	OR	4.05	1.94-8.49	RCT	L	189
			Nausea/vomiting ⁶⁸	OR	2.65	1.03-6.77	RCT	H	189
			Weight gain ⁶⁸	NA	Sig	Sig	RCT	H	376
Venlafaxine	16 (20.5%)	7 (9.0%)	Abdominal pain ⁷⁰	OR	2.36	1.29-4.32	RCT	M	367
			Anorexia ⁷²	OR	4.25	1.55-11.63	RCT	M	323
			Discontinuation due to adverse event ⁴⁰	OR	3.19	1.01-18.70	NMA	H	5,260
			Headache ⁷²	OR	0.56	0.35-0.92	RCT	M	313
			Hypertension ⁷⁰	NA	Sig	Sig	RCT	M	367
			Serious adverse events ⁷⁰	OR	4.14	1.15-14.9	RCT	M	367
			Suicidality ⁴⁰	OR	0.13	0.00-0.55	NMA	H	5,260
Vilazodone	16 (20.5%)	2 (2.6%)	Discontinuation due to adverse event ⁹⁴	OR	8.55	1.13-64.8	RCT	H	526
			Nausea/vomiting ⁹⁴	OR	4.40	2.43-9.76	RCT	H	526

OR – odds ratio, RR – risk ratio, Log OR – log odds ratio, HR – hazard ratio, MD – mean difference, NMA – network meta-analysis, MA – meta-analysis, RCT – randomized controlled trial, C – cohort study, NA – not available, H – high quality, M – medium quality, L – low quality (lower score of either AMSTAR or AMSTAR-Content), Sig – significant difference between medication and placebo without effect size available




Figure 2 Proportion of adverse events covered by the literature that were significantly worse or non-significantly different from placebo, for antidepressants, antipsychotics, anti-attention-deficit/hyperactivity (ADHD) medications, and mood stabilizers in children and adolescents with mental illness. AMI - amisulpride, ATP - amitriptyline, ARI - aripiprazole, ASE - asenapine, ATO - atomoxetine, BUP - bupropion, CBZ - carbamazepine, CIT - citalopram, CLM - clomipramine, CLO - clonidine, CLZ - clozapine, DES - desipramine, DVX - desvenlafaxine, D-AMP - d-amphetamine, DUL - duloxetine, ESC - escitalopram, FLX - fluoxetine, FLU - fluphenazine, FVX - fluvoxamine, GUA - guanfacine, HAL - haloperidol, IMI - imipramine, LAM - lamotrigine, LIT - lithium, LDX - lisdexamphetamine, LOX - loxapine, LUR - lurasidone, MPH - methylphenidate, MIR - mirtazapine, MOD - modafinil, MOL - molindone, NFZ - nefazodone, NOR - nortriptyline, OLA - olanzapine, OXZ - oxcarbazepine, PAL - paliperidone, PAR - paroxetine, QUE - quetiapine, RIS - risperidone, SRT - sertraline, TOP - topiramate, TRIF - trifluoperazine, VPA - valproate, VFX - venlafaxine, VZD - vilazodone, ZIP - ziprasidone

tween mixed SGAs and diabetes (≥ 12 months).

For anti-ADHD medications, no RCT lasted ≥ 6 months, no cohort study 6-12 months, while five cohort studies lasted ≥ 12 months (range: 12-130 months)^{99,174-177}. A large protective association was found between methylphenidate and any cancer (≥ 12 months), which survived after additional analyses from the same database removing mixed medications⁹⁹.

For mood stabilizers, no RCT lasted ≥ 6 months and no cohort studies were identified, so there was no long-term data on adverse events for any mood stabilizer.

DISCUSSION

This meta-review of 80 psychotropic medications summarized data on 78 preselected adverse events in children and adolescents with mental illness, quantifying data for 18 antidepressants

(N=120,637), 15 antipsychotics (N=66,764), seven anti-ADHD medications (N=148,664) and six mood stabilizers (N=1,621).

Overall, the amount of coverage of the preselected adverse events was 0-24.4% for antidepressants (no data for 26 antidepressants), 0-56.4% for antipsychotics (no data for six antipsychotics), 7.7-32.1% for anti-ADHD medications (data for all anti-ADHD medications), and 0-24.4% for mood stabilizers (no data for two mood stabilizers).

Data were reported on $\geq 20\%$ of the preselected adverse events for only six antidepressants (sertraline, escitalopram, paroxetine, fluoxetine, venlafaxine, vilazodone), eight antipsychotics (risperidone, quetiapine, aripiprazole, lurasidone, paliperidone, ziprasidone, olanzapine, asenapine), three anti-ADHD medications (methylphenidate, atomoxetine, guanfacine), and two mood stabilizers (valproic acid, lithium).

Thus, the present meta-review shows that the evidence on ad-

Table 2 Safety of antipsychotics in children and adolescents with any mental illness (adverse events significantly worse than with placebo/controls)

Medication	Adverse events covered by literature		Adverse events worse than placebo		Adverse event	Type of effect size	Effect size	95% CI	Source	Quality	N
	3 (3.8%)	2 (2.6%)	10 (12.8%)	2 (2.6%)							
Mixed antipsychotics	3 (3.8%)	2 (2.6%)	Discontinuation due to adverse event ¹⁰⁴	RR	2.40	1.10-5.30	MA	M	942		
Mixed second-generation antipsychotics	17 (21.8%)	10 (12.8%)	Weight gain ¹⁰⁴	SMD	0.60	0.30-0.90	MA	M	625		
			Akathisia ¹⁰⁷	NNH	20.4	14.1-36.5	MA	M	1,118		
			Any extrapyramidal side effects ¹⁰⁷	NNH	7.5	5.7-11.0	MA	M	1,118		
			Diabetes ¹⁴³	IRR	10.5	2.06-33.2	C	H	37,866		
			Discontinuation due to adverse event ¹⁰⁷	NNH	20.4	13.4-47.5	MA	M	1,118		
			Dystonia ¹⁰⁵	OR	3.90	1.70-8.40	MA	M	666		
			Hyperprolactinemia ¹⁰⁷	NNH	7.9	6.10-11.1	MA	M	1,118		
			Sedation ¹⁰⁷	NNH	4.7	3.90-6.0	MA	M	1,118		
			Tardive dyskinesia ¹⁰⁵	OR	3.90	1.10-14.1	MA	M	666		
			Tremor ¹⁰⁵	OR	3.49	1.50-8.0	MA	M	666		
Amisulpride	2 (2.6%)	1 (1.3%)	Weight gain ¹⁰⁷	NNH	10.0	7.50-14.8	MA	M	1,118		
			Any extrapyramidal side effects ¹²⁴	OR	9.60	1.48-62	RCT	L	27		
			Akathisia ¹⁰²	OR	3.10	1.0-9.0	NMA	M	2,158		
			Any extrapyramidal side effects ¹⁰³	OR	3.80	2.20-6.20	NMA	M	3,258		
			Asthenia ¹⁰⁹	NNH	4.1	3.1-6.2	MA	M	296		
			Anorexia ¹⁰⁹	OR	8.54	2.59-28.1	MA	M	405		
			Increased cholesterol ¹⁰⁸	OR	5.11	1.14-23.0	MA	M	308		
			Fever ¹⁰⁹	RR	2.50	1.40-4.40	MA	L	120		
			Sedation ¹⁰³	OR	5.89	1.23-28.2	MA	M	308		
			Sialorrhea ¹⁰⁹	OR	6.10	2.80-12.2	NMA	M	3,348		
Asenapine	22 (28.2%)	2 (2.6%)	Weight gain ¹⁰³	OR	10.5	1.30-84.2	MA	M	314		
			Increased body mass index ¹³⁶	OR	11.5	1.40-91.6	MA	M	313		
			Increased glucose ¹⁴¹	OR	4.40	2.0-8.90	NMA	M	3,401		
Clozapine	2 (2.6%)	2 (2.6%)	Weight gain	NA	Sig	Sig	RCT	M	306		
			Sedation ¹⁰³	NA	Sig	Sig	RCT	M	403		
			Weight gain ^{101,103}	OR	54.8	3.9-260	NMA	M	3,348		
				OR	13.8	2.20-49.2	NMA	M	3,401		
				SMD	-0.92	-1.61 to -0.22	NMA	M	3,003		

Table 2 Safety of antipsychotics in children and adolescents with any mental illness (adverse events significantly worse than with placebo/controls) (continued)

Medication	Adverse events covered by literature		Adverse events worse than placebo	Adverse event	Type of effect size	Effect size	95% CI	Source	Quality	N
Fluphenazine	2 (2.6%)	0 (0.0%)			OR	59.1	6.66-525	RCT	L	50
Haloperidol	6 (7.7%)	3 (3.8%)		Any extrapyramidal side effects ¹³¹	SMD	1.0	0.2-1.8	NMA	M	3,003
				Sedation ¹⁰¹	Log OR	-1.3	-2.3 to -0.3	NMA	M	3,003
Loxapine	2 (2.6%)	2 (2.6%)		Any extrapyramidal side effects ¹³¹	OR	62.4	7.05-553	RCT	L	50
				Sedation ¹⁰¹	Log OR	-1.9	-3.1 to -0.7	NMA	M	3,003
Lurasidone	33 (42.3%)	1 (1.3%)		Nausea/vomiting ¹⁴²	OR	3.1	1.50-6.60	RCT	M	343
Molindone	10 (12.8%)	3 (3.8%)		Akathisia ¹⁰²	OR	24.1	5.70-102	NMA	M	2,158
				Any extrapyramidal side effects ¹⁰²	OR	10.4	3.0-35.6	NMA	M	2,158
Olanzapine	25 (32.1%)	13 (16.6%)		Sedation ¹⁰²	OR	10.9	2.40-50.2	NMA	M	2,158
				Akathisia ¹⁰²	OR	3.70	1.10-12.7	NMA	M	2,158
				Anemia ¹¹⁹	NA	Sig	Sig	RCT	L	107
				Any extrapyramidal side effects ¹⁰³	OR	6.40	2.40-13.8	NMA	M	3,258
				Increased cholesterol ¹⁰³	MD	4.5	1.2-7.7	NMA	M	1,784
				Increased creatine phosphokinase ¹¹⁹	NA	Sig	Sig	RCT	L	107
				Increased glucose ¹⁰³	MD	2.1	0.1-4.3	NMA	M	1,784
				Hyperprolactinemia ^{101,103}	OR	15.6	4.40-41.1	NMA	M	3,348
				Hypertension ¹³⁰	SMD	0.7	0.3-1.1	NMA	M	3,003
				Liver damage ¹¹³	NA	Sig	Sig	RCT	L	107
				Sexual adverse events ¹⁰⁸	OR	18.7	3.60-96.4	MA	H	265
				Sedation ¹⁰³	MD	11.5	8.80-14.1	MA	L	241
				Increased triglycerides ^{103,113}	OR	8.50	4.0-16.6	NMA	M	3,348
				Weight gain ¹⁰³	OR	5.10	2.80-9.40	MA	M	268
Paliperidone	26 (33.3%)	5 (6.4%)		Akathisia ¹⁰²	MD	20.2	9.8-30.5	NMA	H	1,655
				Any extrapyramidal side effects ¹⁰²	OR	15.1	6.60-31.1	NMA	M	3,401
				Hyperprolactinemia ¹⁰¹	OR	5.60	1.80-17.7	NMA	M	2,158
				Sedation ¹⁰¹	OR	6.30	2.30-16.8	NMA	M	2,158
				Weight gain ¹⁰¹	SMD	0.61	0.35-0.86	NMA	M	3,003
					Log OR	-2.4	-4.4 to -0.3	NMA	M	3,003
					SMD	-0.7	-1.0 to -0.5	NMA	M	3,003

Table 2 Safety of antipsychotics in children and adolescents with any mental illness (adverse events significantly worse than with placebo/controls) (continued)

Medication	Adverse events covered by literature	Adverse events worse than placebo	Adverse event	Type of effect size	Effect size	95% CI	Source	Quality	N			
Quetiapine	37 (47.4%)	5 (6.4%)	Increased cholesterol ¹⁰³	MD	10.8	6.6-145	NMA	M	1,784			
			Hyperprolactinemia ¹⁰¹	SMD	0.4	0.1-0.7	NMA	M	3,003			
			Sedation ¹⁰³	OR	5.40	2.90-9.30	NMA	M	3,348			
			Increased triglycerides ¹⁰³	MD	19.5	11.8-27.2	NMA	M	1,655			
			Weight gain ^{101,103}	OR	6.20	2.60-13.6	NMA	M	3,401			
Risperidone	44 (56.4%)	12 (15.4%)	Alkathisia ¹⁰²	OR	4.0	1.40-10.9	NMA	M	2,158			
			Any extrapyramidal side effects ¹⁰³	OR	3.70	2.20-6.0	NMA	M	3,258			
			Asthenia ¹⁰⁹	OR	3.89	1.77-8.53	MA	M	179			
			Constipation ¹⁰⁹	OR	3.42	1.33-8.80	MA	M	179			
			Gastrointestinal symptoms ¹¹⁵	OR	3.74	1.15-12.2	RCT	H	168			
			Increased glucose ¹⁰³	MD	3.70	1.10-6.40	NMA	M	1,784			
			Hyperprolactinemia ^{101,103}	OR	38.6	8.60-126	NMA	M	1,180			
			Increased appetite ¹⁰⁹	SMD	1.40	0.80-2.0	NMA	M	3,003			
			Nasopharyngitis/upper respiratory tract infection ¹⁰⁹	OR	4.82	2.35-9.88	MA	M	179			
			Sedation ¹⁰³	OR	3.14	1.26-7.80	MA	M	179			
			Tachycardia ¹⁰⁹	OR	7.30	4.60-11.2	NMA	M	3,348			
			Weight gain ^{101,103}	OR	6.87	1.49-31.7	MA	M	179			
			Trifluoperazine	1 (1.3%)	0 (0.0%)	Any extrapyramidal side effects ¹⁰³	OR	6.0	3.0-11.0	NMA	M	3,401
						Dizziness ¹³⁵	SMD	-0.61	-0.89 to -0.32	NMA	M	3,003
						Nausea/vomiting ¹³⁵	OR	20.6	3.50-69.0	NMA	M	3,258
Ziprasidone	25 (32.1%)	4 (5.1%)	Sedation ¹⁰³	OR	9.15	1.20-69.7	RCT	L	283			
			Weight gain ^{101,103}	OR	4.80	1.10-21.1	RCT	L	283			

OR – odds ratio, RR – risk ratio, Log OR – log odds ratio, SMD – standardized mean difference, IRR – incidence rate ratio, NNH – number needed to harm, NMA – network meta-analysis, MA – meta-analysis, RCT – randomized controlled trial, C – cohort study, NA – not available, H – high quality, M – medium quality, L – low quality (lower score of either AMSTAR or AMSTAR-Content), Sig – significant difference between medication and placebo without effect size available

Table 3 Safety of anti-attention-deficit/hyperactivity (ADHD) medications in children and adolescents with any mental illness (adverse events significantly worse than with placebo/controls)

Medication	Adverse events covered by literature	Adverse events worse than placebo	Adverse event	Type of effect size	Effect size	95% CI	Source	Quality	N
Mixed anti-ADHD medications	19 (24.4%)	7 (9.0%)	Abdominal pain ¹⁵⁵	RR	1.44	1.03-2.00	MA	H	2,155
			Anorexia ¹⁵⁵	RR	6.31	2.58-15.5	MA	H	2,467
			Discontinuation due to adverse event ¹⁴⁴	OR	2.30	1.36-3.89	NMA	H	14,346
			Hypertension ¹⁴⁴	SMD	0.09	0.01-0.18	NMA	H	14,346
			Insomnia ¹⁵⁵	RR	3.80	2.12-6.83	MA	H	2,429
			Nausea/vomiting ¹⁵⁵	RR	1.63	1.04-2.56	MA	H	1,579
			Weight loss ¹⁴⁴	SMD	-0.71	-1.15 to -0.27	NMA	H	14,346
Mixed α -2 agonists	5 (6.4%)	1 (1.3%)	Discontinuation due to adverse event ⁴⁹	Log OR	-29.6	-95.5 to -2.6	NMA	M	2,623
Atomoxetine	20 (25.6%)	5 (6.4%)	Anorexia ¹⁴⁷	RR	2.51	1.77-3.57	MA	M	2,179
			Gastrointestinal symptoms ¹⁴⁷	RR	1.76	1.51-2.07	MA	M	3,712
			Hypertension ¹⁴⁴	SMD	0.12	0.02-0.22	NMA	H	14,346
			Nausea/vomiting ¹⁵⁶	RR	1.91	1.24-2.94	MA	L	193
			Weight loss ¹⁴⁴	SMD	-0.84	-1.16 to -0.52	NMA	H	14,346
Clonidine	10 (12.8%)	2 (2.6%)	Hypotension ¹⁴⁹	Hedges' g	0.52	0.15-0.89	MA	M	119
			Sedation ¹⁶⁴	OR	7.67	2.92-20.1	RCT	M	230
d-amphetamine	6 (7.7%)	3 (3.8%)	Anorexia ¹⁷⁰	NA	Sig	Sig	RCT	L	81
			Insomnia ¹⁷⁰	NA	Sig	Sig	RCT	L	81
			Irritability ¹⁷⁰	NA	Sig	Sig	RCT	L	81
Guanfacine	16 (20.5%)	4 (5.1%)	Abdominal pain ¹⁶⁶	OR	4.51	1.34-15.2	RCT	M	455
			Discontinuation due to adverse event ¹⁴⁴	OR	2.64	1.20-5.81	NMA	H	14,346
			QT prolongation ¹⁴⁹	Hedges' g	0.33	0.12-0.54	MA	M	785
			Sedation ¹⁴⁹	RR	2.43	1.06-5.58	MA	M	1,059
Lisdexamphetamine	14 (17.9%)	5 (6.4%)	Anorexia ¹⁵⁵	RR	9.83	5.08-19.0	MA	H	1,081
			Discontinuation due to adverse event ¹⁴⁵	RR	3.11	1.20-3.76	NMA	M	6,931
			Dry mouth ¹⁶⁹	OR	8.63	1.13-66.0	RCT	H	547
			Hypertension ¹⁴⁴	SMD	0.14	0.03-0.25	NMA	H	14,346
			Insomnia ¹⁵⁵	RR	5.91	2.84-12.3	MA	H	1,081
Methylphenidate	25 (32.1%)	5 (6.4%)	Abdominal pain ¹⁵⁴	RR	1.50	1.26-1.79	MA	M	5,983
			Anorexia ¹⁵⁴	RR	3.21	2.61-3.94	MA	M	5,983
			Insomnia ¹⁴⁸	OR	4.66	1.99-10.9	MA	M	749
			Nausea/vomiting ¹⁵⁴	RR	1.38	1.04-1.84	MA	M	2,630
			Weight loss ¹⁴⁴	SMD	-0.77	-1.09 to -0.45	NMA	H	14,346
Modafinil	13 (16.7%)	3 (3.8%)	Anorexia ¹⁵³	RR	5.02	2.55-9.89	MA	M	921
			Insomnia ¹⁵³	RR	6.16	3.40-11.2	MA	M	921
			Weight loss ¹⁴⁴	SMD	-0.93	-1.59 to -0.26	NMA	H	14,346

OR – odds ratio, RR – risk ratio, Log OR – log odds ratio, SMD – standardized mean difference, NMA – network meta-analysis, MA – meta-analysis, RCT – randomized controlled trial, NA – not available, H – high quality, M – medium quality, L – low quality (lower score of either AMSTAR or AMSTAR-Content), Sig – significant difference between medication and placebo without effect size available

Table 4 Safety of mood stabilizers in children and adolescents with any mental illness (adverse events significantly worse than with placebo/controls)

Medication	Adverse events covered by literature	Adverse events worse than placebo	Adverse event	Type of effect size	Effect size	95% CI	Source	Quality	N
Mixed mood stabilizers	4 (5.1%)	1 (1.3%)	Sedation ¹⁰⁷	NNH	9.5	6.3-23.5	MA	L	469
Carbamazepine	7 (9.0%)	0 (0.0%)							
Lamotrigine	11 (14.1%)	0 (0.0%)							
Lithium	16 (20.5%)	0 (0.0%)							
Oxcarbazepine	11 (14.1%)	4 (5.1%)	Discontinuation due to adverse event ¹⁸¹	OR	6.19	1.31-29.3	RCT	M	116
			Nausea/vomiting ¹⁸¹	OR	3.66	1.33-10.1	RCT	M	116
			Sedation ¹⁸¹	OR	6.89	1.47-32.4	RCT	M	116
			Weight gain ¹⁸¹	NA	Sig	Sig	RCT	M	116
Topiramate	15 (19.2%)	1 (1.3%)	Anorexia ¹⁸²	OR	21.7	1.19-398	RCT	M	56
Valproate	19 (24.4%)	4 (5.1%)	Leukocytopenia ¹⁸⁰	NA	Sig	Sig	RCT	H	150
			Sedation ¹⁰⁷	NNH	7.8	5.3-15.0	MA	L	231
			Thrombocytopenia ¹⁸⁰	NA	Sig	Sig	RCT	H	150
			Weight gain ¹⁰⁷	Effect size	0.4	0.07-0.73	MA	L	231

OR – odds ratio, RR – risk ratio, NNH – number needed to harm, MA – meta-analysis, RCT – randomized controlled trial, NA – not available, H – high quality, M – medium quality, L – low quality (lower score of either AMSTAR or AMSTAR-Content), Sig – significant difference between medication and placebo without effect size available

verse events of psychotropic medications in children and adolescents is modest overall, and that psychostimulants are the drugs which have been most studied up to now.

The main adverse events for antidepressants were (in descending order of number of medications associated with the specific event): nausea/vomiting, discontinuation due to adverse event, extrapyramidal side effects, weight gain, sedation, diarrhea, headache and anorexia. Based on the safety/coverage ratio among agents with $\geq 20\%$ adverse event coverage, the safest profile emerged for escitalopram and fluoxetine, and the worst for venlafaxine. These data confirm, and put in a more comprehensive framework, the findings of a previous NMA on antidepressants in children and adolescents⁴⁰ (focusing, however, on efficacy as its primary outcome), which showed that both fluoxetine and escitalopram were not associated with more drop-outs than placebo, while venlafaxine was, with a moderate effect size (OR=3.19). In the same NMA, fluoxetine was found to be the only antidepressant significantly superior to placebo with respect to its impact on depressive symptoms (SMD=-0.51). Merging the safety results of the present meta-review with the available evidence on efficacy from that NMA⁴⁰, fluoxetine probably has the best harm-benefit ratio among all antidepressants for youth, and might be proposed as the first-line treatment for depressive disorders in children and adolescents.

The main adverse events for antipsychotics were (in descending order of number of medications associated with the specific event): sedation, extrapyramidal side effects, weight gain, hyperprolactinemia, increased cholesterol, and glucose increase.

Based on the safety/coverage ratio among agents with $\geq 20\%$ adverse event coverage, the safest profile emerged for lurasidone, and the worst for olanzapine. These data confirm in part, and put in a more comprehensive framework, the findings of the largest NMA of antipsychotics in children and adolescents with schizophrenia¹⁰¹ (which, however, focused on efficacy as primary outcome). In the same NMA, the only antipsychotic superior to all others in terms of efficacy was clozapine, and no further difference emerged among other antipsychotics, except for ziprasidone being inferior to molindone, olanzapine and risperidone, and fluphenazine being inferior to all other antipsychotics.

Merging the safety results of the present meta-review with available evidence on efficacy¹⁰¹, lurasidone might be proposed as the first-line treatment for schizophrenia spectrum disorders in children and adolescents. Less tolerable yet effective medications can be used as second-line treatments, tailoring the choice to each individual patient's expectations and safety priorities (e.g., sexually active subjects might prefer agents not increasing prolactin). Importantly, clozapine should be considered only for treatment-resistant cases, given the lack of evidence regarding its safety in children and adolescents, and its poor safety profile in adults¹⁹², which can be expected to be similar in children and adolescents, if not worse.

The main adverse events for anti-ADHD medications were (in descending order of number of medications associated with the specific event): anorexia, insomnia, weight loss, abdominal pain, hypertension, and sedation. Based on safety/coverage ratio among agents with $\geq 20\%$ adverse event coverage, the safest pro-

file emerged for methylphenidate, and the worst for atomoxetine and guanfacine. Our comprehensive meta-review provides a finer-grained insight into the adverse events of anti-ADHD medications, while the largest NMA to date¹⁴⁴ did not reveal differences among these drugs concerning tolerability. Somewhat surprisingly, methylphenidate was also protective against cancer when long follow-up was considered, with such protective association surviving additional analyses excluding mixed medications⁹⁹. Further research is warranted on this protective effect.

Our meta-review shows that both atomoxetine and methylphenidate induce weight loss, consistent with previous findings¹⁴⁴. Sedation was only observed with the alpha-2 agonists clonidine and guanfacine. Clinically, this effect can sometimes be exploited to counter insomnia, but residual daytime sedation may impair cognitive performance in subjects with ADHD. In terms of efficacy, in the above-mentioned NMA¹⁴⁴, only methylphenidate outperformed placebo (SMD=-0.82) according to teachers' ratings. Moreover, methylphenidate was superior to atomoxetine (SMD=0.22). Considering the available safety and efficacy data, methylphenidate might be considered the first-line treatment for ADHD in children and adolescents.

The main adverse events for mood stabilizers were (with the same number of medications associated with the specific event) sedation and weight gain. Based on the safety/coverage ratio among agents with ≥20% adverse event coverage, the safest event profile emerged for lithium, and the worst for valproate. While the lack of any association between lithium and thyroid/kidney damage¹⁸⁸ as well as weight gain¹⁹⁰ is likely due to the small sample size of the included RCTs (N=124 and N=31, respectively), and the short duration of one RCT (3 months)¹⁸⁸, significant lithium-induced weight gain would have emerged during the six-month RCT¹⁹⁰. Considering the well-established efficacy of lithium, which is the first-line treatment in adolescent bipolar disorder according to international guidelines¹⁹³, currently available data on the harm-benefit ratio favor the choice of lithium among mood stabilizers in youth. However, long-term cohort studies in this age group are clearly warranted. All antipsychotics have more adverse events than lithium according to this meta-review, except for lurasidone, which seems to have a comparably safe profile and could be preferred to lithium for the treatment of bipolar depression^{193,194}.

The results of this meta-review need to be interpreted considering some limitations. First, data for adverse events are lacking for some, and limited for many of the reviewed psychotropic medications. Absence of evidence for certain adverse events cannot be taken as evidence of their absence. Therefore, a more comprehensive reporting of adverse events is strongly recommended in studies concerning the use of psychotropic medications in children and adolescents.

Second, information on adverse events is mostly based on spontaneous reports. While these will underestimate the frequency of such events, the use of rating scales might increase the level of noise. Interviews and/or self-report scales would assure a more comprehensive capturing of adverse events, and applying appropriate thresholds for severity and frequency could enhance

the signal-to-noise ratio.

Third, long-term and rare adverse events are likely underrepresented in the reviewed data, that are based mostly on short- and medium-term RCTs, with only eight cohort studies of sufficient methodological quality providing longer-term data. Fourth, we did not differentiate the adverse events based on dose effects due to limited data. Fifth, we took a transdiagnostic approach in order to capture all available information. Although certain adverse events could possibly differ across the various mental disorders, no clear evidence exists for this possibility, and other patient- and medication-related factors that are transdiagnostic (e.g., age, treatment-naïveté, dose, co-medications) are likely much more important than diagnosis.

Of course, safety of medications needs to be considered along with their efficacy. This was not a focus of this large-scale meta-review, but we discussed our findings in the context of efficacy data from the largest and most recent NMA or MA for the respective medication class for its main indication. Finally, this meta-review does not include data on strategies to prevent or mitigate adverse events of psychotropic medications in youth. While this is clearly an important area, this topic is beyond the scope of the present review and needs to be considered on the basis of targeted reviews and studies focusing on specific adverse events of individual medications¹⁹⁵⁻²⁰¹.

In summary, the results of this meta-review have several clinical implications, which can guide the use of psychotropic medications in children and adolescents. First, for some medications, there are no or very insufficient high-quality adverse event data in this age group, which should caution their use. Second, within each of the four major classes, we provide a hierarchy of medications on the basis of the available safety evidence: the preferred agents are likely to be fluoxetine and escitalopram among antidepressants, lurasidone among antipsychotics, methylphenidate among anti-ADHD medications, and lithium among mood stabilizers. By contrast, potentially least preferred agents based on safety are likely to be venlafaxine among antidepressants, olanzapine among antipsychotics, atomoxetine and guanfacine among anti-ADHD medications, and valproate among mood stabilizers.

Together with the efficacy data for these medications, the results of this comprehensive and updated meta-review of top-tier evidence regarding the safety of antidepressants, antipsychotics, anti-ADHD medications and mood stabilizers in children and adolescents can inform clinical practice, research and treatment guidelines.

ACKNOWLEDGEMENTS

E.G. Ostinelli is supported by the National Institute for Health Research (NIHR) Oxford Cognitive Health Clinical Research Facility and the NIHR Oxford Health Biomedical Research Centre (grant BRC-1215-20005).

REFERENCES

1. Parellada M. Why psychogeriatrics starts right after adolescence. *Eur Child Adolesc Psychiatry* 2013;22:391-3.
2. Kessler RC, Berglund P, Demler O et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. *Arch Gen Psychiatry* 2005;62:593-602.

3. Correll CU, Galling B, Pawar A et al. Comparison of early intervention services vs treatment as usual for early-phase psychosis: a systematic review, meta-analysis, and meta-regression. *JAMA Psychiatry* 2018;75:555-65.
4. Chia MF, Cotton S, Folia K et al. Early intervention for bipolar disorder – Do current treatment guidelines provide recommendations for the early stages of the disorder? *J Affect Disord* 2019;257:669-77.
5. Correll CU, Kratochvil CJ, March JS. Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics. *J Clin Psychiatry* 2011;72:655-70.
6. Kornø KT, Aagaard L. Off-label prescribing of antipsychotics in a Danish child and adolescent mental health center: a register-based study. *J Res Pharm Pract* 2018;7:205-9.
7. Panther SG, Knotts AM, Odom-Maryon T et al. Off-label prescribing trends for ADHD medications in very young children. *J Pediatr Pharmacol Ther* 2017;22:423-9.
8. Braüner JV, Johansen LM, Roesbjerg T et al. Off-label prescription of psychopharmacological drugs in child and adolescent psychiatry. *J Clin Psychopharmacol* 2016;36:500-7.
9. Sharma AN, Arango C, Coghill D et al. BAP Position Statement: Off-label prescribing of psychotropic medication to children and adolescents. *J Psychopharmacol* 2016;30:416-21.
10. Shekelle P, Maglione M, Bagley S. Efficacy and comparative effectiveness of off-label use of atypical antipsychotics. *Agency Healthc Res Qual* 2007;6.
11. Hung C, Yu NW, Liu CY et al. The impact of the duration of an untreated episode on improvement of depression and somatic symptoms. *Neuropsychiatr Dis Treat* 2015;11:2245-52.
12. Dagani J, Signorini G, Nielssen O et al. Meta-analysis of the interval between the onset and management of bipolar disorder. *Can J Psychiatry* 2017;62:247-58.
13. Van Meter AR, Burke C, Youngstrom EA et al. The bipolar prodrome: meta-analysis of symptom prevalence prior to initial or recurrent mood episodes. *J Am Acad Child Adolesc Psychiatry* 2016;55:543-55.
14. Compton MT, Gordon TL, Goulding SM et al. Patient-level predictors and clinical correlates of duration of untreated psychosis among hospitalized first-episode patients. *J Clin Psychiatry* 2011;72:225-32.
15. Albert U, Barbaro F, Bramante S et al. Duration of untreated illness and response to SRI treatment in obsessive-compulsive disorder. *Eur Psychiatry* 2019;58:19-26.
16. Benatti B, Camuri G, Dell'Osso B et al. Which factors influence onset and latency to treatment in generalized anxiety disorder, panic disorder, and obsessive-compulsive disorder? *Int Clin Psychopharmacol* 2016;31:347-52.
17. Kisely S, Scott A, Denney J et al. Duration of untreated symptoms in common mental disorders: association with outcomes. *Br J Psychiatry* 2006;189:79-80.
18. Rubio JM, Correll CU. Duration and relevance of untreated psychiatric disorders, 1: Psychotic disorders. *J Clin Psychiatry* 2017;78:358-9.
19. Rubio JM, Correll CU. Duration and relevance of untreated psychiatric disorders, 2: Nonpsychotic psychiatric disorders and substance use disorders. *J Clin Psychiatry* 2017;78:464-5.
20. Penttilä M, Jaäskeläinen E, Hirvonen N et al. Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis. *Br J Psychiatry* 2014;205:88-94.
21. Ghio L, Gotelli S, Marcenaro M et al. Duration of untreated illness and outcomes in unipolar depression: a systematic review and meta-analysis. *J Affect Disord* 2014;152-154:45-51.
22. Compton MT, Gordon TL, Weiss PS et al. The “doses” of initial, untreated hallucinations and delusions: a proof-of-concept study of enhanced predictors of first-episode symptomatology and functioning relative to duration of untreated psychosis. *J Clin Psychiatry* 2011;72:1487-93.
23. Hung CI, Liu CY, Yang CH. Untreated duration predicted the severity of depression at the two-year follow-up point. *PLoS One* 2017;12:e0185119.
24. Medeiros GC, Senço SB, Lafer B et al. Association between duration of untreated bipolar disorder and clinical outcome: data from a Brazilian sample. *Rev Bras Psiquiatr* 2016;38:6-10.
25. Kular A, Perry BI, Brown L et al. Stigma and access to care in first-episode psychosis. *Early Interv Psychiatry* 2019;13:1208-13.
26. Gronholm PC, Thornicroft G, Laurens KR et al. Mental health-related stigma and pathways to care for people at risk of psychotic disorders or experiencing first-episode psychosis: a systematic review. *Psychol Med* 2017;47:1867-79.
27. Gerlinger G, Hauser M, De Hert M et al. Personal stigma in schizophrenia spectrum disorders: a systematic review of prevalence rates, correlates, impact and interventions. *World Psychiatry* 2013;12:155-64.
28. Ray WA, Stein CM, Murray KT et al. Association of antipsychotic treatment with risk of unexpected death among children and youths. *JAMA Psychiatry* 2019;76:162-71.
29. Galling B, Roldán A, Nielsen RE et al. Type 2 diabetes mellitus in youth exposed to antipsychotics: a systematic review and meta-analysis. *JAMA Psychiatry* 2016;73:247-59.
30. Isacson G, Rich CL. Antidepressant drugs and the risk of suicide in children and adolescents. *Pediatr Drugs* 2014;16:115-22.
31. Hennissen L, Bakker MJ, Banaschewski T et al. Cardiovascular effects of stimulant and non-stimulant medication for children and adolescents with ADHD: a systematic review and meta-analysis of trials of methylphenidate, amphetamines and atomoxetine. *CNS Drugs* 2017;31:199-215.
32. Zito JM, Burcu M. Stimulants and pediatric cardiovascular risk. *J Child Adolesc Psychopharmacol* 2017;27:538-45.
33. Fish FA, Kannankeril PJ. Diagnosis and management of sudden death in children. *Curr Opin Pediatr* 2012;24:592-602.
34. Bell GS, Mula M, Sander JW. Suicidality in people taking antiepileptic drugs: what is the evidence? *CNS Drugs* 2009;23:281-92.
35. Dragioti E, Solmi M, Favaro A et al. Association of antidepressant use with adverse health outcomes: a systematic umbrella review. *JAMA Psychiatry* 2019;76:1241-55.
36. Sharma A, Guski LS, Freund N et al. Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports. *BMJ* 2016;352:i65.
37. Barbu C, Cipriani A, Geddes JR. Antidepressants and suicide symptoms: compelling new insights from the FDA's analysis of individual patient level data. *Evid Based Ment Health* 2008;11:34-6.
38. Singh T, Prakash A, Rais T et al. Decreased use of antidepressants in youth after US Food and Drug Administration black box warning. *Psychiatry* 2009;6:30-4.
39. Fornaro M, Anastasia A, Valchera A et al. The FDA “black box” warning on antidepressant suicide risk in young adults: more harm than benefits? *Front Psychiatry* 2019;10:294.
40. Cipriani A, Zhou X, Del Giovane C et al. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. *Lancet* 2016;388:881-90.
41. Cortese S, Tomlinson A, Cipriani A. Meta-review: network meta-analyses in child and adolescent psychiatry. *J Am Acad Child Adolesc Psychiatry* 2019;58:167-79.
42. Solmi M, Correll CU, Carvalho AF et al. The role of meta-analyses and umbrella reviews in assessing the harms of psychotropic medications: beyond qualitative synthesis. *Epidemiol Psychiatr Sci* 2018;27:537-42.
43. Chen H, Cohen P, Chen S. How big is a big odds ratio? Interpreting the magnitudes of odds ratios in epidemiological studies. *Commun Stat - Simul Comput* 2010;39:860-4.
44. Correll CU, Rubio JM, Inczedy-Farkas G et al. Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. *JAMA Psychiatry* 2017;74:675-84.
45. Shea BJ, Grimshaw JM, Wells GA et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. *BMC Med Res Methodol* 2007;7(10).
46. Higgins JPT, Savovic J, Page MJ et al. Revised Cochrane risk-of-bias tool for randomized trials (RoB 2). <https://sites.google.com/site/riskofbiastool/welcome/rob-2-0-tool/current-version-of-rob-2>.
47. Wells G, Shea B, O'Connell J et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
48. Catalá-López F, Hutton B, Núñez-Beltrán A et al. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: a systematic review with network meta-analyses of randomised trials. *PLoS One* 2017;12:e0180355.
49. Dobson ET, Bloch MH, Strawn JR. Efficacy and tolerability of pharmacotherapy for pediatric anxiety disorders: a network meta-analysis. *J Clin Psychiatry* 2019;80:17r12064.
50. Uthman OA, Abdulmalik J. Comparative efficacy and acceptability of pharmacotherapeutic agents for anxiety disorders in children and adolescents: a mixed treatment comparison meta-analysis. *Curr Med Res Opin* 2010;26:53-9.
51. Maneeton N, Srisurapanont M. Tricyclic antidepressants for depressive disorders in children and adolescents: a meta-analysis of randomized-controlled trials. *J Med Assoc Thai* 2000;83:1367-74.
52. Hetrick SE, McKenzie JE, Cox GR et al. Newer generation antidepressants for depressive disorders in children and adolescents. *Cochrane Database Syst*

- Rev 2012;11:CD004851.
53. Julious SA. Efficacy and suicidal risk for antidepressants in paediatric and adolescent patients. *Stat Methods Med Res* 2013;22:190-218.
 54. Bridge JA, Iyengar S, Salary CB et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. *JAMA* 2007;297:1683-96.
 55. Dubicka B, Hadley S, Roberts C. Suicidal behaviour in youths with depression treated with new-generation antidepressants: meta-analysis. *Br J Psychiatry* 2006;189:393-8.
 56. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. *Arch Gen Psychiatry* 2006;63:332-9.
 57. Strawn JR, Welge JA, Wehry AM et al. Efficacy and tolerability of antidepressants in pediatric anxiety disorders: a systematic review and meta-analysis. *Depress Anxiety* 2015;32:149-57.
 58. Rohden AI, Benchaya MC, Camargo RS et al. Dropout prevalence and associated factors in randomized clinical trials of adolescents treated for depression: systematic review and meta-analysis. *Clin Ther* 2017;39:971-92.
 59. Locher C, Koechlin H, Zion SR et al. Efficacy and safety of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and placebo for common psychiatric disorders among children and adolescents: a systematic review and meta-analysis. *JAMA Psychiatry* 2017;74:1011-20.
 60. Otasowie J, Castells X, Ehimare UP et al. Tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents. *Cochrane Database Syst Rev* 2014;9:CD006997.
 61. Ipser JC, Stein DJ, Hawkrigde S et al. Pharmacotherapy for anxiety disorders in children and adolescents. *Cochrane Database Syst Rev* 2009;3:CD005170.
 62. Wang Z, Whiteside SPH, Sim L et al. Comparative effectiveness and safety of cognitive behavioral therapy and pharmacotherapy for childhood anxiety disorders: a systematic review and meta-analysis. *JAMA Pediatr* 2017;171:1049-56.
 63. Rojas-Mirquez JC, Rodriguez-Zuñiga MJM, Bonilla-Escobar FJ et al. Nocebo effect in randomized clinical trials of antidepressants in children and adolescents: systematic review and meta-analysis. *Front Behav Neurosci* 2014;8:375.
 64. Hazell P, O'Connell D, Heathcote D et al. Tricyclic drugs for depression in children and adolescents. *Cochrane Database Syst Rev* 2002;2:CD002317.
 65. Kye CH, Waterman GS, Ryan ND et al. A randomized, controlled trial of amitriptyline in the acute treatment of adolescent major depression. *J Am Acad Child Adolesc Psychiatry* 1996;35:1139-44.
 66. Conners CK, Casat CD, Gualtieri CT et al. Bupropion hydrochloride in attention deficit disorder with hyperactivity. *J Am Acad Child Adolesc Psychiatry* 1996;35:1314-21.
 67. Geller B, Cooper TB, Graham DL et al. Pharmacokinetically designed double-blind placebo-controlled study of nortriptyline in 6- to 12-year-olds with major depressive disorder. *J Am Acad Child Adolesc Psychiatry* 1992;31:34-44.
 68. Wagner KD, Ambrosini P, Rynn M et al. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. *JAMA* 2003;290:1033-41.
 69. Wagner KD, Berard R, Stein MB et al. A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. *Arch Gen Psychiatry* 2004;61:1153-62.
 70. Emslie GJ, Findling RL, Yeung PP et al. Venlafaxine ER for the treatment of pediatric subjects with depression: results of two placebo-controlled trials. *J Am Acad Child Adolesc Psychiatry* 2007;46:479-88.
 71. Emslie GJ, Prakash A, Zhang Q et al. A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder. *J Child Adolesc Psychopharmacol* 2014;24:170-9.
 72. Rynn M. Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials. *Am J Psychiatry* 2007;164:290-300.
 73. Emslie GJ, Ventura D, Korotzer A et al. Escitalopram in the treatment of adolescent depression: a randomized placebo-controlled multisite trial. *J Am Acad Child Adolesc Psychiatry* 2009;48:721-9.
 74. March JS, Entusah AR, Rynn M et al. A randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder. *Biol Psychiatry* 2007;62:1149-54.
 75. Pfizer. Double-blind, placebo-controlled study of venlafaxine ER in children and adolescents with generalized anxiety disorder. *EMA Paediatric Web Synopsis*, 2011.
 76. Wagner KD, Jonas J, Findling RL et al. A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. *J Am Acad Child Adolesc Psychiatry* 2006;45:280-8.
 77. Von Knorring AL, Olsson GI, Thomsen PH et al. A randomized, double-blind, placebo-controlled study of citalopram in adolescents with major depressive disorder. *J Clin Psychopharmacol* 2006;26:311-5.
 78. Emslie GJ, Heiligenstein JH, Wagner KD et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. *J Am Acad Child Adolesc Psychiatry* 2002;41:1205-15.
 79. Geller DA, Hoog SL, Heiligenstein JH et al. Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial. *J Am Acad Child Adolesc Psychiatry* 2001;40:773-9.
 80. Riddle MA, Reeve EA, Yaryura-Tobias JA et al. Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial. *J Am Acad Child Adolesc Psychiatry* 2001;40:222-9.
 81. Emslie GJ, Wagner KD, Kutcher S et al. Paroxetine treatment in children and adolescents with major depressive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. *J Am Acad Child Adolesc Psychiatry* 2006;45:709-19.
 82. Geller DA, Wagner KD, Emslie G et al. Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. *J Am Acad Child Adolesc Psychiatry* 2004;43:1387-96.
 83. Robb AS, Cueva JE, Sporn J et al. Sertraline treatment of children and adolescents with posttraumatic stress disorder: a double-blind, placebo-controlled trial. *J Child Adolesc Psychopharmacol* 2010;20:463-71.
 84. March JS, Biederman J, Wolkow R et al. Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. *JAMA* 1998;280:1752-6.
 85. Biederman J, Baldessarini RJ, Wright V et al. A double-blind placebo controlled study of desipramine in the treatment of ADD: I. Efficacy. *J Am Acad Child Adolesc Psychiatry* 1989;28:777-84.
 86. Strawn JR, Prakash A, Zhang Q et al. A randomized, placebo-controlled study of duloxetine for the treatment of children and adolescents with generalized anxiety disorder. *J Am Acad Child Adolesc Psychiatry* 2015;54:283-93.
 87. Findling RL, Robb A, Bose A. Escitalopram in the treatment of adolescent depression: a randomized, double-blind, placebo-controlled extension trial. *J Child Adolesc Psychopharmacol* 2013;23:468-80.
 88. March JS. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. *JAMA* 2004;292:807-20.
 89. Pine DS, Walkup JT, Labellarte MJ et al. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. *N Engl J Med* 2001;344:1279-85.
 90. Keller MB, Ryan ND, Strober M et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. *J Am Acad Child Adolesc Psychiatry* 2001;40:762-72.
 91. Mosholder AD. Nefazodone hydrochloride (Serzone) - Review and evaluation of clinical data. https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/020152s032_nefazodone_Serzone_Clinical_BPCA.pdf.
 92. Atkinson S, Lubaczewski S, Ramaker S et al. Desvenlafaxine versus placebo in the treatment of children and adolescents with major depressive disorder. *J Child Adolesc Psychopharmacol* 2018;28:55-65.
 93. Emslie GJ, Wells TG, Prakash A et al. Acute and longer-term safety results from a pooled analysis of duloxetine studies for the treatment of children and adolescents with major depressive disorder. *J Child Adolesc Psychopharmacol* 2015;25:293-305.
 94. Durgam S, Chen C, Migliore R et al. A phase 3, double-blind, randomized, placebo-controlled study of vilazodone in adolescents with major depressive disorder. *Paediatr Drugs* 2018;20:353-63.
 95. Herscu P, Handen BL, Arnold LE et al. The SOFIA study: negative multicenter study of low dose fluoxetine on repetitive behaviors in children and adolescents with autistic disorder. *J Autism Dev Disord* (in press).
 96. Hollander E, Phillips A, Chaplin W et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. *Neuropsychopharmacology* 2005;30:582-9.
 97. DeVeaux-Geiss J, Moroz G, Biederman J et al. Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder - a multicenter trial. *J Am Acad Child Adolesc Psychiatry* 1992;31:45-9.
 98. Gracious BL, Fontanella CA, Phillips GS et al. Antidepressant exposure and risk of fracture among Medicaid-covered youth. *J Clin Psychiatry* 2016;77:e950-6.
 99. Steinhilber HC, Helenius D. The association between medication for attention-deficit/hyperactivity disorder and cancer. *J Child Adolesc Psychopharmacol* 2013;23:208-13.

100. Valuck RJ, Libby AM, Sills MR et al. Antidepressant treatment and risk of suicide attempt by adolescents with major depressive disorder: a propensity-adjusted retrospective cohort study. *CNS Drugs* 2004;18:1119-32.
101. Krause M, Zhu Y, Huhn M et al. Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: a network meta-analysis. *Eur Neuropsychopharmacol* 2018;28:659-74.
102. Pagsberg AK, Tarp S, Glinborg D et al. Acute antipsychotic treatment of children and adolescents with schizophrenia-spectrum disorders: a systematic review and network meta-analysis. *J Am Acad Child Adolesc Psychiatry* 2017;56:191-202.
103. Cohen D, Bonnot O, Bodeau N et al. Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian meta-analysis. *J Clin Psychopharmacol* 2012;32:309-16.
104. Stafford MR, Mayo-Wilson E, Loucas CE et al. Efficacy and safety of pharmacological and psychological interventions for the treatment of psychosis and schizophrenia in children, adolescents and young adults: a systematic review and meta-analysis. *PLoS One* 2015;10:e0117166.
105. Ardizzone I, Nardecchia F, Marconi A et al. Antipsychotic medication in adolescents suffering from schizophrenia: a meta-analysis of randomized controlled trials. *Psychopharmacol Bull* 2010;43:45-66.
106. Schneider-Thoma J, Efthimiou O, Bighelli I et al. Second-generation antipsychotic drugs and short-term somatic serious adverse events: a systematic review and meta-analysis. *Lancet Psychiatry* 2019;6:753-65.
107. Correll CU, Sheridan EM, DelBello MP. Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. *Bipolar Disord* 2010;12:116-41.
108. Seida JC, Schouten JR, Mousavi SS et al. First- and second-generation antipsychotics for children and young adults. Rockville: Agency for Healthcare Research and Quality, 2012.
109. Fallah MS, Shaikh MR, Neupane B et al. Atypical antipsychotics for irritability in pediatric autism: a systematic review and network meta-analysis. *J Child Adolesc Psychopharmacol* 2019;29:168-80.
110. Maneeton B, Putthirisi S, Maneeton N et al. Quetiapine monotherapy versus placebo in the treatment of children and adolescents with bipolar depression: a systematic review and meta-analysis. *Neuropsychiatr Dis Treat* 2017;13:1023-32.
111. Maneeton N, Maneeton B, Putthirisi S et al. Aripiprazole in acute treatment of children and adolescents with autism spectrum disorder: a systematic review and meta-analysis. *Neuropsychiatr Dis Treat* 2018;14:3063-72.
112. Fung LK, Mahajan R, Nozzolillo A et al. Pharmacologic treatment of severe irritability and problem behaviors in autism: a systematic review and meta-analysis. *Pediatrics* 2016;137 (Suppl. 2):S124-35.
113. Pringsheim T, Lam D, Ching H et al. Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials. *Drug Saf* 2011;34:651-68.
114. Kumar A, Datta SS, Wright SD et al. Atypical antipsychotics for psychosis in adolescents. *Cochrane Database Syst Rev* 2013;10:CD009582.
115. Aman MG, Bukstein OG, Gadow KD et al. What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder? *J Am Acad Child Adolesc Psychiatry* 2014;53:47-60.
116. Connor DF, McLaughlin TJ, Jeffers-Terry M. Randomized controlled pilot study of quetiapine in the treatment of adolescent conduct disorder. *J Child Adolesc Psychopharmacol* 2008;18:140-56.
117. Hollander E, Wasserman S, Swanson EN et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. *J Child Adolesc Psychopharmacol* 2006;16:541-8.
118. Ichikawa H, Mikami K, Okada T et al. Aripiprazole in the treatment of irritability in children and adolescents with autism spectrum disorder in Japan: a randomized, double-blind, placebo-controlled study. *Child Psychiatry Hum Dev* 2017;48:796-806.
119. Kryzhanovskaya L, Schulz SC, McDougle C et al. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. *J Am Acad Child Adolesc Psychiatry* 2009;48:60-70.
120. Loebel A, Brams M, Goldman RS et al. Lurasidone for the treatment of irritability associated with autistic disorder. *J Autism Dev Disord* 2016;46:1153-63.
121. Marcus RN, Owen R, Kamen L et al. A Placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. *J Am Acad Child Adolesc Psychiatry* 2009;48:1110-9.
122. McCracken JT, McGough J, Shah B et al. Risperidone in children with autism and serious behavioral problems. *N Engl J Med* 2002;347:314-21.
123. Owen R, Sikich L, Marcus RN et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. *Pediatrics* 2009;124:1533-40.
124. Paillère-Martinot ML, Lecrubier Y, Martinot JL et al. Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. *Am J Psychiatry* 1995;152:130-4.
125. Pathak S, Findling RL, Earley WR et al. Efficacy and safety of quetiapine in children and adolescents with mania associated with bipolar I disorder. *J Clin Psychiatry* 2013;74:e100-9.
126. Remington G, Sloman L, Konstantareas M et al. Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. *J Clin Psychopharmacol* 2001;21:440-4.
127. Findling RL, Robb A, Nyilas M et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. *Am J Psychiatry* 2008;165:1432-41.
128. Reyes M, Buitelaar J, Toren P et al. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. *Am J Psychiatry* 2006;163:402-10.
129. Singh J, Robb A, Vijapurkar U et al. A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents. *Biol Psychiatry* 2011;70:1179-87.
130. Tohen M, Kryzhanovskaya L, Carlson G et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. *Am J Psychiatry* 2007;164:1547-56.
131. Pool D, Bloom W, Mielke DH et al. A controlled evaluation of loxitane in seventy five adolescent schizophrenic patients. *Curr Ther Res Clin Exp* 1976;19:99-104.
132. Haas M, Unis AS, Armenteros J et al. A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. *J Child Adolesc Psychopharmacol* 2009;19:611-21.
133. Findling RL, Nyilas M, Forbes RA et al. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. *J Clin Psychiatry* 2009;70:1441-51.
134. Findling RL, McKenna K, Earley WR et al. Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial. *J Child Adolesc Psychopharmacol* 2012;22:327-42.
135. Findling RL, Cavuş I, Pappadopulos E et al. Ziprasidone in adolescents with schizophrenia: results from a placebo-controlled efficacy and long-term open-extension study. *J Child Adolesc Psychopharmacol* 2013;23:531-44.
136. Findling RL, Landbloom RP, Mackle M et al. Safety and efficacy from an 8 week double-blind trial and a 26 week open-label extension of asenapine in adolescents with schizophrenia. *J Child Adolesc Psychopharmacol* 2015;25:384-96.
137. Goldman R, Loebel A, Cucchiaro J et al. Efficacy and safety of lurasidone in adolescents with schizophrenia: a 6-week, randomized placebo-controlled study. *J Child Adolesc Psychopharmacol* 2017;27:516-25.
138. Haas M, Delbello MP, Pandina G et al. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. *Bipolar Disord* 2009;11:687-700.
139. Hagman J, Gralla J, Sigel E et al. A double-blind, placebo-controlled study of risperidone for the treatment of adolescents and young adults with anorexia nervosa: A pilot study. *J Am Acad Child Adolesc Psychiatry* 2011;50:915-24.
140. Findling RL, Cavuş I, Pappadopulos E et al. Efficacy, long-term safety, and tolerability of ziprasidone in children and adolescents with bipolar disorder. *J Child Adolesc Psychopharmacol* 2013;23:545-57.
141. Findling RL, Landbloom RL, Szegedi A et al. Asenapine for the acute treatment of pediatric manic or mixed episode of bipolar I disorder. *J Am Acad Child Adolesc Psychiatry* 2015;54:1032-41.
142. DelBello MP, Goldman R, Phillips D et al. Efficacy and safety of lurasidone in children and adolescents with bipolar I depression: a double-blind, placebo-controlled study. *J Am Acad Child Adolesc Psychiatry* 2017;56:1015-25.
143. Andrade SE, Lo JC, Roblin D et al. Antipsychotic medication use among children and risk of diabetes mellitus. *Pediatrics* 2011;128:1135-41.
144. Cortese S, Adamo N, Del Giovane C et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. *Lancet Psychiatry* 2018;5:727-38.
145. Joseph A, Ayyagari R, Xie M et al. Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison. *Eur Child Adolesc Psychiatry* 2017;26:875-97.
146. Storebø OJ, Ramstad E, Krogh HB et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). *Cochrane Database Syst Rev* 2015;11:CD009885.
147. Schwartz S, Correll CU. Efficacy and safety of atomoxetine in children and

- adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression. *J Am Acad Child Adolesc Psychiatry* 2014;53:174-87.
148. Ching C, Eslick GD, Poulton AS. Evaluation of methylphenidate safety and maximum-dose titration rationale in attention-deficit/hyperactivity disorder: a meta-analysis. *JAMA Pediatr* 2019;173:630-9.
 149. Hirota T, Schwartz S, Correll CU. Alpha-2 agonists for attention-deficit/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy. *J Am Acad Child Adolesc Psychiatry* 2014;53:153-73.
 150. Coughlin CG, Cohen SC, Mulqueen JM et al. Meta-analysis: reduced risk of anxiety with psychostimulant treatment in children with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol* 2015;25:611-7.
 151. Schachter HM, Pham B, King J et al. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. *CMAJ* 2001;165:1475-88.
 152. Bangs ME, Wietecha LA, Wang S et al. Meta-analysis of suicide-related behavior or ideation in child, adolescent, and adult patients treated with atomoxetine. *J Child Adolesc Psychopharmacol* 2014;24:426-34.
 153. Wang SM, Han C, Lee SJ et al. Modafinil for the treatment of attention-deficit/hyperactivity disorder: a meta-analysis. *J Psychiatr Res* 2017;84:292-300.
 154. Holmskov M, Storebø OJ, Moreira-Maia CR et al. Gastrointestinal adverse events during methylphenidate treatment of children and adolescents with attention deficit hyperactivity disorder: a systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. *PLoS One* 2017;12:e0178187.
 155. Punja S, Shamseer L, Hartling L et al. Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents. *Cochrane Database Syst Rev* 2016;2:CD009996.
 156. Patra S, Nebhinani N, Viswanathan A et al. Atomoxetine for attention deficit hyperactivity disorder in children and adolescents with autism: a systematic review and meta-analysis. *Autism Res* 2019;12:542-52.
 157. Newcorn JH, Kratochvil CJ, Allen AJ et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. *Am J Psychiatry* 2008;165:721-30.
 158. Findling RL, Quinn D, Hatch SJ et al. Comparison of the clinical efficacy of twice-daily Ritalin® and once-daily Equasym™ XL with placebo in children with attention deficit/hyperactivity disorder. *Eur Child Adolesc Psychiatry* 2006;15:450-9.
 159. Greenhill LL, Biederman J, Boellner SW et al. A randomized, double-blind, placebo-controlled study of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry* 2006;45:503-11.
 160. Kahbazi M, Ghoreishi A, Rahiminejad F et al. A randomized, double-blind and placebo-controlled trial of modafinil in children and adolescents with attention deficit and hyperactivity disorder. *Psychiatry Res* 2009;168:234-7.
 161. Biederman J, Lopez FA, Boellner SW et al. A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. *Pediatrics* 2002;110:258-66.
 162. Biederman J, Swanson JM, Wigal SB et al. A comparison of once-daily and divided doses of modafinil in children with attention-deficit/hyperactivity disorder: a randomized, double-blind, and placebo-controlled study. *J Clin Psychiatry* 2006;67:727-35.
 163. Hervas A, Huss M, Johnson M et al. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, Phase III trial. *Eur Neuropsychopharmacol* 2014;24:1861-72.
 164. Jain R, Segal S, Kollins SH et al. Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry* 2011;50:171-9.
 165. Michelson D, Faries D, Wernicke J et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. *Pediatrics* 2001;108:E83.
 166. Wilens TE, Bukstein O, Brams M et al. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry* 2012;51:74-85.e2.
 167. Biederman J, Swanson JM, Wigal SB et al. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study. *Pediatrics* 2005;116:e777-84.
 168. Gittelman-Klein R, Klein DE, Katz S et al. Comparative effects of methylphenidate and thioridazine in hyperkinetic children: I. Clinical results. *Arch Gen Psychiatry* 1976;33:1217-31.
 169. Newcorn JH, Nagy P, Childress AC et al. Randomized, double-blind, placebo-controlled acute comparator trials of lisdexamfetamine and extended-release methylphenidate in adolescents with attention-deficit/hyperactivity disorder. *CNS Drugs* 2017;31:999-1014.
 170. Conners CK, Taylor E, Meo G et al. Magnesium pemoline and dextroamphetamine: a controlled study in children with minimal brain dysfunction. *Psychopharmacologia* 1972;26:321-36.
 171. Daviss WB, Patel NC, Robb AS et al. Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis. *J Am Acad Child Adolesc Psychiatry* 2008;47:189-98.
 172. Tumuluru R V, Corbett-Dick P, Aman MG et al. Adverse events of atomoxetine in a double-blind placebo-controlled study in children with autism. *J Child Adolesc Psychopharmacol* 2017;27:708-14.
 173. Spencer TJ, Abikoff HB, Connor DF et al. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: a 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study. *Clin Ther* 2006;28:402-18.
 174. McAfee AT, Holdridge KC, Johannes CB et al. The effect of pharmacotherapy for attention deficit hyperactivity disorder on risk of seizures in pediatric patients as assessed in an insurance claims database. *Curr Drug Saf* 2008;3:123-31.
 175. Winterstein AG, Gerhard T, Shuster J et al. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder. *Pediatrics* 2007;120:e1494-501.
 176. Dalsgaard S, Kvist AP, Leckman JF et al. Cardiovascular safety of stimulants in children with attention-deficit/hyperactivity disorder: a nationwide prospective cohort study. *J Child Adolesc Psychopharmacol* 2014;24:302-10.
 177. Hemmer SA, Pasternak JF, Zecker SG et al. Stimulant therapy and seizure risk in children with ADHD. *Pediatr Neurol* 2001;24:99-102.
 178. Hirota T, Veenstra-Vanderweele J, Hollander E et al. Antiepileptic medications in autism spectrum disorder: a systematic review and meta-analysis. *J Autism Dev Disord* 2014;44:948-57.
 179. Jochim J, Rifkin-Zybutz R, Geddes J et al. Valproate for acute mania. *Cochrane Database Syst Rev* 2019; 10:CD004052.
 180. Wagner KD, Redden L, Kowatch RA et al. A double-blind, randomized, placebo-controlled trial of divalproex extended-release in the treatment of bipolar disorder in children and adolescents. *J Am Acad Child Adolesc Psychiatry* 2009;48:519-32.
 181. Wagner KD, Kowatch RA, Emslie GJ et al. A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. *Am J Psychiatry* 2006;163:1179-86.
 182. Delbello MP, Findling RL, Kushner S et al. A pilot controlled trial of topiramate for mania in children and adolescents with bipolar disorder. *J Am Acad Child Adolesc Psychiatry* 2005;44:539-47.
 183. Belsito KM, Law PA, Kirk KS et al. Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial. *J Autism Dev Disord* 2001;31:175-81.
 184. Hellings JA, Weckbaugh M, Nickel EJ et al. A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. *J Child Adolesc Psychopharmacol* 2005;15:682-92.
 185. Hollander E, Chaplin W, Soorya L et al. Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. *Neuropsychopharmacology* 2010;35:990-8.
 186. Rezaei V, Mohammadi MR, Ghanizadeh A et al. Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. *Prog Neuro-Psychopharmacology Biol Psychiatry* 2010;34:1269-72.
 187. Blader JC, Schooler NR, Jensen PS et al. Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy. *Am J Psychiatry* 2009;166:1392-401.
 188. Yuan J, Song J, Zhu D et al. Lithium treatment is safe in children with intellectual disability. *Front Mol Neurosci* 2018;11:425.
 189. Cueva JE, Overall JE, Small AM et al. Carbamazepine in aggressive children with conduct disorder: a double-blind and placebo-controlled study. *J Am Acad Child Adolesc Psychiatry* 1996;35:480-90.
 190. Findling RL, McNamara NK, Pavuluri M et al. Lithium for the maintenance treatment of bipolar I disorder: a double-blind, placebo-controlled discontinuation study. *J Am Acad Child Adolesc Psychiatry* 2019;58:287-96.
 191. Findling RL, Chang K, Robb A et al. Adjunctive maintenance lamotrigine for pediatric bipolar I disorder: a placebo-controlled, randomized withdrawal study. *J Am Acad Child Adolesc Psychiatry* 2015;54:1020-31.

192. Huhn M, Nikolakopoulou A, Schneider-Thoma J et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. *Lancet* 2019;394:939-51.
193. Yatham LN, Kennedy SH, Parikh SV et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. *Bipolar Disord* 2018;20:97-170.
194. Fornaro M, De Berardis D, Perna G et al. Lurasidone in the treatment of bipolar depression: systematic review of systematic reviews. *Biomed Res Int* 2017;2017:3084859.
195. Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. *World Psychiatry* 2018;17:341-356.
196. Ellul P, Delorme R, Cortese S. Metformin for weight gain associated with second-generation antipsychotics in children and adolescents: a systematic review and meta-analysis. *CNS Drugs* 2018;32:1103-12.
197. Correll CU, Sikich L, Reeves G et al. Metformin add-on vs. antipsychotic switch vs. continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial. *World Psychiatry* 2020;19:69-80.
198. Correll CU. Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. *J Am Acad Child Adolesc Psychiatry* 2008;47:9-20.
199. Luft MJ, Lamy M, DelBello MP et al. Antidepressant-induced activation in children and adolescents: risk, recognition and management. *Curr Probl Pediatr Adolesc Health Care* 2018;48:50-62.
200. Wigal SB. Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults. *CNS Drugs* 2009;23(Suppl. 1):21-31.
201. Montejo AL, Montejo L, Baldwin DS. The impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical management. *World Psychiatry* 2018;17:3-11.

DOI:10.1002/wps.20765